Company Overview and News

1
0
National Vision Announces 2018 College Scholarship Recipients

2018-06-12 globenewswire
DULUTH, Ga., June 12, 2018 (GLOBE NEWSWIRE) -- National Vision Holdings, Inc., (NASDAQ:EYE) one of the nation’s largest optical retailers providing quality, affordable eye care and eyewear, is pleased to announce the selection of five high school seniors as recipients of the 2018 National Vision College Scholarship Program. Recipients will receive $2,500 to fund the advancement of their education. The award is renewable for up to three additional years, for a total potential scholarship of $10,000 per student.
EYE

0
National Vision Holdings Inc (EYE) Fundamental Valuation Report

2018-05-12 valuewalk
This Report was generated using the tools available on StockCalc.com. Patchell Brook Equity Analytics Inc. emphasizes that the user assumes all risks associated with the use of this report or the Stockcalc website including, but not limited to, all terms and conditions mentioned in the legal disclaimer. To access all of the tools on Stockcalc, including more detailed valuation reports and the models used to generate these valuations, please subscribe for a free 30 day trial of Stockcalc here.
EYE SFIX HOME

0
EYE / National Vision Holdings, Inc. null

2018-04-28 sec.gov
Simpson Thacher & Bartlett llp EYE

0
EYE / National Vision Holdings, Inc. null

2018-04-28 sec.gov
Simpson Thacher & Bartlett llp
EYE

1
EYE / National Vision Holdings, Inc. DEFA14A

2018-04-25 sec.gov
UNITED STATES
EYE

1
EYE / National Vision Holdings, Inc. DEF 14A

2018-04-25 sec.gov
TABLE OF CONTENTS
EYE

1534
Stocks To Watch: Earnings Blockbusters And Trump Talks Drug Prices

2018-04-21 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
VR GIS CAT PSX TEVA FSCT FIXX ZNGA WYN MS MMP ABBV UMRX AMGN AMC TRV BILI UNUM DVMT CZR JNJ GHG VZ MSFT HBI ALDR MGM DVD FB EPD ZION VRX AGN CL KO INTC WYNN LLY GSK AVY NEXA NXP MU GNPX KHC SBUX LQ LM BYD IVZ MBIN TXN XOM TWX MS.PRE RDI IPIC MS.PRF MS.PRG CNK MS.PRA AMZN GM.WS.A TWTR GM.WS.B GM.WS.C GSK VLKAY EBAY NBL VRX LMHA PCAR KMB AIG TWC LMHB CMG NAV MS.PRI GOOGL MS.PRK IONS ABBV PTCT LVS QCOM BA GM.WSB FOXA PFE HAL XLNX EYE ETH RRR VMW MCS CHTR RDIB BIIB GWW GM PAA DAL LAD DIS BMY MBNC IBM MPLX ALKS CMCSA FTI.WI FMC V NAVI PEP T IQ MRK CVX SNE HPQ BPMP

1
0
0
EYE / National Vision Holdings, Inc. FORM S-1MEF

2018-03-15 sec.gov
As filed with the Securities and Exchange Commission on March 15, 2018 Registration No. 333-
EYE

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

4h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

5h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to EYE / National Vision Holdings, Inc. on message board site Silicon Investor.

EYES Second Sight-Eyeglasses for the Blind help them see FEYE
Blue Eyes Crying in the Rain Mobileye
HAWKEYE Gold Grants 985,000 Incentive Stock Options HAWKEYE Gold Grants 985,000 Incentive Stock Options
HAWKEYE GOLD PURCHASE TOP PROPERTY - YUKON HAWKEYE GOLD. TSX SYMBOL - HGO
Intellicorp - Keep A Watchful Eye On It Keep Your Eye On The Ball - Watch List
CUSIP: 63845R107